Sunshine Biopharma, Inc. (SBFMW)

Market Cap	4.47M
Revenue (ttm)	34.87M
Net Income (ttm)	-5.13M
Shares Out	2.71M
EPS (ttm)	-7.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Open	0.1700
Previous Close	0.1700
Day's Range	0.1700 - 0.1700
52-Week Range	0.1700 - 0.1700
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 31, 2025

About SBFMW

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-parti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Steve Slilaty
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: SBFMW
• Website: https://sunshinebiopharma.com

Financial Performance

In 2024, Sunshine Biopharma's revenue was $34.87 million, an increase of 44.75% compared to the previous year's $24.09 million. Losses were -$5.13 million, 13.9% more than in 2023.